Drug Trial Radar · NCT05985694
AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma
Last checked: Nov 19, 2026Latest source record: Sep 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Nov 27, 2023
Primary completion
Jan 28, 2025
Study completion Apr 27, 2025
Sponsor
- Lead sponsor
- Advagene Biopharma Co. Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Taipei Medical University Hospital
- First posted
- Aug 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial aims to investigate patients with poorly controlled, moderate to severe eosinophilic asthma. The main questions it seeks to answer are 1. Could the AD17002 intranasal immunomodulator improve the clinical condition of eosinophilic asthmatic patients? 2. Could patients self-administer AD17002 via the intranasal route? 3. Is the AD17002 at multiple doses safe for asthmatic patients? 4. Participants will be asked to self-administer two doses per week for a total of 6 weeks (11 doses). A diary on AD17002 usage, adverse events, and reliever medication will be recorded.
Conditions
- Eosinophilic Asthma
Interventions
AD17002Drug
The dosing days of AD17002 are: Days 1, 4, 8, 11, 15, 18, 22, 25, 29, and 32.
PlaceboDrug
Formulation buffer. Dosing days: 1, 4, 8, 11, 15, 18, 22, 25, 29, 32.
Primary outcomes
What the sponsor says the trial is designed to measure.
- FEV1 improvementTime frame: Day 1 to Day 78
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Taipei Medical University Hospital
Taipei, Taiwan, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.